Antibodies against phospho p38

Manufactured by Cell Signaling Technology

Sourced in United States

Antibodies against phospho-p38 are laboratory reagents used to detect and quantify the phosphorylated form of the p38 mitogen-activated protein kinase (MAPK) in biological samples. These antibodies specifically recognize the activated, phosphorylated state of the p38 MAPK, allowing researchers to study the activation of this signaling pathway.

Automatically generated - may contain errors

Lab products found in correlation

Phospho jnk, by Cell Signaling Technology (4 mentions) Phospho erk1 2, by Cell Signaling Technology (2 mentions) Recombinant m csf, by R&D Systems (2 mentions) Anti nfatc1 antibody, by BD (2 mentions) Phospho iκbα, by Cell Signaling Technology (2 mentions) Rankl, by R&D Systems (2 mentions) Recombinant human il 1β, by Thermo Fisher Scientific (1 mentions) Cy3 conjugated secondary antibody, by Santa Cruz Biotechnology (1 mentions) N acetylcysteine, by Merck Group (1 mentions) Epigallocatechin 3 gallate, by Merck Group (1 mentions) Horseradish peroxidase, by Santa Cruz Biotechnology (1 mentions) β tubulin, by Santa Cruz Biotechnology (1 mentions) N vanillylnonanamide, by Merck Group (1 mentions) Antibodies against iκbα, by Santa Cruz Biotechnology (1 mentions) Criterion xt bis tris precast gel, by Bio-Rad (1 mentions) Protease and phosphatase inhibitor, by Roche (1 mentions) Lipofectamine 3000, by Thermo Fisher Scientific (1 mentions) Trizol ls, by Thermo Fisher Scientific (1 mentions) Trizol reagent, by Merck Group (1 mentions) Miscript sybr green pcr kit, by Qiagen (1 mentions)

Close spelling variants of this product

Phospho-p38 (477 citations) Specific antibodies against phospho-p38 (3 citations) Antibodies against p38, (2 citations) Mouse monoclonal antibodies against phospho-p38 (2 citations)

6 protocols using antibodies against phospho p38

Molecular Signaling Pathway Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

(-)-epigallocatechin-3-gallate (EGCG), N-acetylcysteine (NAC), and N-vanillylnonanamide (NVN) were obtained from Sigma Aldrich Co. Ltd. (St. Louis, MO). Recombinant human IL-1β was purchased from GIBCO BRL (Grand Island, NY). The inhibitors, BAY 11–7085 for NF-κB, SB 203580 for p38, and PD 98059 for MEK 1, were purchased from Calbiochem (La Jolla, CA). EGCG and NAC were dissolved in H₂O. NVN, BAY 11–7085, SB 203580, and PD 98059 were dissolved in dimethyl sulfoxide, methyl alcohol, or H₂O. The final vehicle concentration was adjusted to 0.1% (v/v), and the control medium contained the same quantity of vehicle. Antibodies against phospho-p38, p38, phospho-ERK, and ERK were obtained from Cell Signaling Technology (Beverly, MA). Antibodies against IκBα, β-tubulin, horseradish peroxidase, and Cy3-conjugated secondary antibodies were obtained from Santa Cruz Biotechnology (Santa Cruz, CA).

Lee J.Y., Paik J.S., Yun M., Lee S.B, & Yang S.W. (2016). The Effect of (-)-Epigallocatechin-3-Gallate on IL-1β Induced IL-8 Expression in Orbital Fibroblast from Patients with Thyroid-Associated Ophthalmopathy. PLoS ONE, 11(2), e0148645.

+ Open protocol

+ Expand

Mutant ATP7B Phosphorylation Signaling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against phospho‐p38, phospho‐JNK, phospho‐extracellular signal‐regulated kinase (ERK), p38, JNK, and ERK were from Cell Signaling Technology (Beverly, MA). The DNAs of ATP7A and its mutants were already reported.13 DNAs of flag‐tagged MKK3, MKK4, MKK6, and MKK7 were obtained from Addgene (Cambridge MA). To obtain the R778L, D765N, L776V, A874V, and L1083F mutants of ATP7B, the phosphorylated enhanced green fluorescent protein (GFP) C1‐ATP7B construct was used as a template and site‐directed mutagenesis was performed according to the manufacturer's instructions using the QuickChange kit (Stratagene, La Jolla, CA). Other reagents, antibodies, DNAs, and viruses have been reported.14

Chesi G., Hegde R.N., Iacobacci S., Concilli M., Parashuraman S., Festa B.P., Polishchuk E.V., Di Tullio G., Carissimo A., Montefusco S., Canetti D., Monti M., Amoresano A., Pucci P., van de Sluis B., Lutsenko S., Luini A, & Polishchuk R.S. (2016). Identification of p38 MAPK and JNK as new targets for correction of Wilson disease‐causing ATP7B mutants. Hepatology (Baltimore, Md.), 63(6), 1842-1859.

+ Open protocol

+ Expand

Antibody Signaling Pathway Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against phospho-p38, phospho-ERK1/2, phospho-JNK, IκB-α, and GAPDH were purchased from Cell Signaling Technology (Beverly, MA). Total p38, ERK1/2, and JNK antibodies were from Santa Cruz Biotechnology (Dallas, Texas). Bovine pancreas RNase A, lipofectamine 3000, TRIzol LS, SYTO RNASelect Green fluorescent cell stain, and Quant-iT^™ RNA assay kit were from Invitrogen Life Technology (Carlsbad, CA). The TLR ligands, poly(I:C), Pam3Cys and CpG, were from Enzo Life (Plymouth Meeting, PA). DNase was from Thermo Scientific Inc. (Waltham, MA). Imiquimod (R837, TLR7 ligand) and CL075 (TLR7/8 ligand) were from Invivogen (San Diego, CA). Human cfB antibody and cobra venom factor (CVF) were purchased from Complement Technology (Texas). TRIzol reagent used to extract RNA from cell or tissues and HRP-conjugated donkey anti-goat IgG are from Sigma-Aldrich (St. Louis, MO). Protease and phosphatase inhibitors were from Roche Diagnostics (Indianapolis, IN). miRNA mimics were synthesize by Integrated DNA Technologies (Coralville, IA) with sequences listed in Table 1. miScript II RT kit, miScript SYBR green PCR kit and miRNA primers for qRT-PCR were purchased from Qiagen (Valencia, CA). Criterion^™ XT Bis-Tris Precast gels were purchased from Bio-Rad (Hercules, CA). Luminata Forte Western HRP substrate was from Millipore Corporation (Billerica, MA).

Zou L., Feng Y., Xu G., Jian W, & Chao W. (2016). Splenic RNA and microRNA mimics promote complement factor B production and the alternative pathway activation via innate immune signaling. Journal of immunology (Baltimore, Md. : 1950), 196(6), 2788-2798.

+ Open protocol

+ Expand

LPS-Induced Inflammation Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

LPS (Escherichia coli strain O111:B4) was obtained from Sigma (L2630; Sigma, St. Louis, MO, USA). PZH powder was obtained from Zhangzhou Pien Tze Huang Pharmaceutical Co., Ltd (Zhangzhou, China). The powder was dissolved in phosphate buffered solution (PBS) and ultrasonicated at 70 Hz for 40 min. Then, the supernatant was collected for in vitro assays, and the suspension was used for the in vivo assays. Stattic (Cat# HY-13818), INT-777 (Cat# HY-15677), INT-767 (Cat# HY-12434) and GW4064 (Cat# HY-50108) were purchased from MedChemExpress (Monmouth Junction, NJ, USA) and dissolved in dimethyl sulfoxide (DMSO). Cholestyramine resin was purchased from Shanghai Yuanye Bio-Technology Co., Ltd (Shanghai, China). Antibodies against phospho-p38 (Cat# 4511s), p38 (Cat# 9218s), phospho-JNK (Cat# 4668s), JNK (Cat# 9252s), phospho-ERK1/2 (Cat# 4377s), ERK1/2 (Cat# 9102s), phospho-p65 (Cat# 3033s), p65 (Cat# 8242s), A20 (Cat# 5630s), and STAT3 (Cat# 9139s, CST) were purchased from Cell Signalling Technology (Boston, MA, USA). Antibodies against glyceraldehyde-3-phosphate dehydrogenase (GAPDH) (Cat# AC002), β-actin (Cat# AC002) and phospho-STAT3 (Cat# AC004) were obtained from ABclonal Technology (Wuhan, China). Antibodies against TGR5 (Cat# ab72608) were obtained from Abcam (Cambridge, UK).

Li B., Zhang Y., Liu X., Zhang Z., Zhuang S., Zhong X., Chen W., Hong Y., Mo P., Lin S., Wang S, & Yu C. (2023). Traditional Chinese medicine Pien-Tze-Huang ameliorates LPS-induced sepsis through bile acid-mediated activation of TGR5-STAT3-A20 signalling. Journal of Pharmaceutical Analysis, 14(4), 100915.

+ Open protocol

+ Expand

Molecular Signaling Pathways Analysis

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against phospho-p38, phospho-ERK, phospho-JNK, phospho-Akt, phospho-IκBα, and phospho-p65 were purchased from Cell Signaling Technology (Danvers, MA, USA). Monoclonal anti-β-actin antibody was obtained from Sigma-Aldrich (St. Louis, MO, USA), and anti-Nfatc1 antibody was purchased from BD Pharmingen (San Diego, CA, USA). Recombinant M-CSF and RANKL were purchased from R & D Systems (Minneapolis, MN, USA). DPHC was isolated from Ishige okamurae, and the method of isolation as well as the purity and structure of DPHC were confirmed by spectroscopy [9 (link)].

Ihn H.J., Kim J.A., Cho H.S., Shin H.I., Kim G.Y., Choi Y.H., Jeon Y.J, & Park E.K. (2017). Diphlorethohydroxycarmalol from Ishige okamurae Suppresses Osteoclast Differentiation by Downregulating the NF-κB Signaling Pathway. International Journal of Molecular Sciences, 18(12), 2635.

+ Open protocol

+ Expand

Regulatory Signaling Pathway Modulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Antibodies against phospho-p38, phospho-JNK, phospho-ERK, and phospho-IκBα were purchased from Cell Signaling Technology (Danvers, MA, United States). Anti-NFATc1 antibody was purchased from BD Pharmingen^TM (San Diego, CA, United States), and antibody against IRF8 was obtained from Santa Cruz Biotechnology. Recombinant M-CSF and RANKL were obtained from R&D Systems (Minneapolis, MN, United States). Fetal bovine serum (FBS) and α-minimum essential medium (α-MEM) were obtained from Gibco BRL (Grand Island, NY, United States). KP-A038 is the imidazobenzimidazole compound of in-house chemical library and the chemical name of KP-A038 is (2-([1,1′-biphenyl]-4-yl)-1-(2-(piperidin-1-yl)ethyl)-1H-benzo[d]imidazo[1,2-a]imidazole (Figure 1). KP-A038 was synthesized as described previously (Supplementary Figure S1; Kim et al., 2014 (link)), and dissolved in DMSO for further experiments.

Ihn H.J., Lee T., Lee D., Bae J.S., Kim S.H., Jang I.H., Bae Y.C., Shin H.I, & Park E.K. (2019). Inhibitory Effect of KP-A038 on Osteoclastogenesis and Inflammatory Bone Loss Is Associated With Downregulation of Blimp1. Frontiers in Pharmacology, 10, 367.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!